Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Sees Significant Decline in Short Interest

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) saw a large decrease in short interest during the month of January. As of January 15th, there was short interest totaling 284,944 shares, a decrease of 27.1% from the December 31st total of 391,100 shares. Based on an average trading volume of 239,638 shares, the short-interest ratio is presently 1.2 days. Approximately 1.5% of the shares of the stock are sold short. Approximately 1.5% of the shares of the stock are sold short. Based on an average trading volume of 239,638 shares, the short-interest ratio is presently 1.2 days.

Artiva Biotherapeutics Stock Performance

Shares of ARTV opened at $3.89 on Friday. The company’s 50 day moving average price is $4.19 and its 200 day moving average price is $3.54. Artiva Biotherapeutics has a 52 week low of $1.47 and a 52 week high of $7.36. The company has a market capitalization of $95.50 million, a PE ratio of -1.51 and a beta of 2.92.

Artiva Biotherapeutics (NASDAQ:ARTV) last released its earnings results on Wednesday, November 12th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. On average, equities analysts forecast that Artiva Biotherapeutics will post -4.95 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Ground Swell Capital LLC acquired a new position in Artiva Biotherapeutics in the 2nd quarter worth about $38,000. Prelude Capital Management LLC bought a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at approximately $41,000. Bank of America Corp DE increased its holdings in Artiva Biotherapeutics by 225.8% in the third quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after buying an additional 11,190 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new position in Artiva Biotherapeutics during the second quarter valued at approximately $48,000. Finally, Bridgeway Capital Management LLC bought a new position in Artiva Biotherapeutics during the second quarter valued at approximately $53,000.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. Wedbush boosted their target price on Artiva Biotherapeutics from $18.00 to $23.00 and gave the stock an “outperform” rating in a research report on Friday, October 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Tuesday. Jefferies Financial Group upgraded shares of Artiva Biotherapeutics to a “strong-buy” rating in a report on Tuesday, November 18th. Needham & Company LLC reissued a “buy” rating and issued a $18.00 target price on shares of Artiva Biotherapeutics in a research report on Friday, October 17th. Finally, HC Wainwright boosted their price target on shares of Artiva Biotherapeutics from $12.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, November 12th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Artiva Biotherapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $19.00.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.